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Abstract  
Heart failure (HF) management is challenging due to high clinical heterogeneity of this 
syndrome, which makes patients responding differently to evidence-based standard therapy 
established by the current reductionist approach. Better understanding of the genetic/ and 
epigenetic interactions may clarify molecular signatures underlying maladaptive responses in 
HF, including metabolic shift, myocardial injury, fibrosis, and mitochondrial dysfunction. 
DNA methylation, histone modifications and micro-RNA (miRNAs), which may also be 
major epigenetic players in the pathogenesis of HF. DNA hypermethylation of the kruppel-
like factor 15 (KLF15) gene plays a key role in switching the failing heart from oxidative to 
glycolytic metabolism. Moreover, hypomethylation at H3K9 promoter level of atrial 
natriuretic peptide (ANP) and brain natriuretic peptide (BNP) genes also lead to reactivation 
of fetal genes in man. The role of miRNAs has been investigated in HF patients undergoing 
heart transplantation, for whom miR-10a, miR-155, miR-31, and miR-92 may be putative 
useful prognostic biomarkers. Recently, higher RNA methylation was observed in ischemic 
human hearts, opening the era of “epitranscriptome” in the pathogenesis of HF. Currently, 
hydralazine, statins, apabetalone, a d omega-3 polyunsatured fatty acids (PUFA) are being 
tested in clinical trials to provide epigenetic-driven therapeutic interventions. Moreover, 
network-oriented analyses could advance current medical practice, by focusing on protein-
protein interactions (PPIs) perturbing the cardiac interactome. In this review, we provide an 
epigenetic map of maladaptive responses in HF patients. Furthermore, we propose the “EPi-
transgeneratIonal network mOdeling for STratificatiOn of heaRt Morbidity” (EPIKO-
STORM), a clinical research strategy offering novel opportunities to stratify the natural 
history of disease. HF. 
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1. Introduction  
Heart failure (HF) is a complex disease resulting from structural or functional dysfunction of 
ventricular filling or ejection of blood.
1,2
 HF arises as the culmination of a wide range of 
disease processes, including genetic disorders, ischemic disease, metabolic disease, and 
hypertension. Coronary atherosclerosis, aging, diabetes, and obesity are major clinical risk 
factors for HF (Figure 1).
1,2
 According to the latest guidelines of cardiological societies
3,4
, 
HF patients are classified according to their left ventricular ejection fraction (EF) value in 
three groups: 1) HF with reduced EF (HFrEF), EF being <40%, 2) HF with mid-range EF 
(HFmrEF), with EF between 40-49%, and 3) HF with preserved EF (HFpEF), with EF >50%. 
Usually, physicians additionally stratify HF patients according to the ACC/AHA Heart 
Failure classification system including stage A-D 
3,4
 which places HF patients in one of four 
categories based on heart structural alterations. In detail, stage A patients are at risk for HF 
but have not yet developed structural heart changes, e.g. patients with diabetes, coronary heart 
disease (CHD) without previous myocardial infarction; stage B patients show structural heart 
disease, e.g. reduced EF, left ventricular hypertrophy, chamber enlargement, but have not yet 
developed symptoms of HF; stage C patients who have developed clinical HF, whereas stage 
D patients require advanced intervention, e.g. cardiac resynchronization therapy (CRT), left 
ventricular assist device (LVAD) and heart transplantation (HTx).
3-6
 
This approach implies the need for a deeper knowledge of mechanistic links among genetic 
and epigenetic events governing the pathophysiology of HF, leading to personalized 
“precision medicine” therapy of disease. The epigenome comprises a large spectrum of 
molecular changes leading to a functional reinterpretation of DNA sequence by dynamic 
activation/repression of specific genes, without changing nucleotide sequence.
7-12
 The main 
epigenetic determinants are DNA and mRNA methylation, post-translational histone/non-
histone modifications, and non-coding RNA.
7-12
 These molecular signatures can be 
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meiotically (transgenerational effect) and mitotically transmitted across several generations 
representing an additional modality for the inheritance of cardiovascular (CV) diseases 
(Figure 2).
13-15
 
The goal of our review is to present a picture of putative epigenetic-sensitive mechanisms 
underlying cardiac remodeling in HF patients. Moreover, we report the main clinical trials 
testing the role of epigenetic-sensitive drugs (epidrugs) in advancing the HF management. 
Finally, we propose the “EPi-transgeneratIonal networK mOdeling for STratificatiOn of 
heaRt Morbidity” (EPIKO-STORM), a clinical research program that may unveil epigenetic 
changes over time and useful biomarkers and drug targets. 
2. A focus on the current therapeutic paradigm of HF  
The current therapeutic paradigm for HFrEF patients focuses on reducing congestive 
symptoms and mortality rate by inhibiting both the adrenergic nervous system (ANS) and the 
renin-angiotensin-aldosterone system (RAAS).
3-5 
The most effective RAAS inhibitors are 
angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blockers (ARBs), 
mineralcorticoid receptor antagonists (MRAs), and angiotensin receptor-neprilysin inhibitor 
(ARNI), which can reduce morbidity and mortality in chronic HFrEF patients.
3,4,16
 
Remarkably, RAAS hyperactivation is a prominent target in treatment of HFrEF and (likely) 
HFmrEF patients, but not only in order to control congestion. Indeed, RAAS inhibitors have 
synergicistic action with beta-blockers (BB) that are still the most effective therapy in 
promoting reverse remodeling and improving beta-adrenergic and heart-rate responsiveness.
16 
17 
Moreover, BB reduce mortality and sudden death by 30-40% in patients treated with 
ACEi
17
 
18
 by modulating end-organ response to the autonomic storm, and they can also inhibit 
myocyte apoptosis
18 19
, while vagal stimulation is able to affect interleukin-6 levels in 
advanced HF.
19 20
 However, BB are not able to provide equal benefit in each patient; for 
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instance, in the case of bucindolol, two polymorphisms of beta-1 adrenergic receptor, e.g., 
Arg-389 homozygosis and Gly-389 heterozigosis were associated with positive and negative 
clinical response to bucindolol, respectively.
20 21
 Remarkably, BB are also the most effective 
therapeutic agents providing changes in myocardial gene expression (epigenetic-like), 
regulating pathways of contractility and pathologic hypertrophy in HF patients vs placebo.
21 22 
Currently, no guideline exists for specific treatment of HFpEF, owing to a great clinical 
heterogeneity of these patients who are complicated by multiple comorbidities as well as 
different etiology and pathophysiology.
22,23,24 
HFpEF patients seem to be less susceptible to 
conventional pharmacotherapy and many clinical trials did not provide solid evidence about 
treatments able to alter the natural history of this condition.
3,23,24 
Interestingly, the sodium-
glucose cotransporter 2 inhibitors (SGLT2i) acting as glucose-lowering agents, e.g. 
empagliflozin, have been successively applied for management of diabetic patients affected 
by HFrEF and HFpEF improving hemodynamic parameters and reducing their 
hospitalization.
3
 Although their mechanisms of action are not well understood, a putative 
epigenetic regulation underlying the protecting CV effect exerted by SGLT2i was found.
25,26
 
Moreover, SGLT2i might have a putative effect also in man by decreasing RAAS 
activation.
27,28
 Indeed, there is tubule-glomerular feedback in patients with type 1 diabetes 
before and after administration of empagliflozin.
27,28
 The study results disclosed the 
mechanism by which the RAAS axis is tapered down by the effect of SGLT2i on tubular 
sodium and glucose reabsorption.
27,28
 This evidence was confirmative of what previously 
observed in animal models.
25,26
 Thus, we emphasize the need to further explore if the current 
approved drugs may restore the aberrant epigenetic-sensitive pathway in pathophysiologically 
distinct HF conditions.  
3. Basic mechanisms of epigenetic regulation  
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The cell-specific patterns of epigenetic modifications, mainly DNA methylation, histone 
modifications, and miRNAs, are affected by environmental exposures and represent a strong 
mechanistic link for the etiology of HF (Figure 3).
26 29
 DNA methylation is catalyzed by 
DNA methyltransferases (DNMTs) enzymes, which are classified in DNMT1, 2, or 3 able to 
add a methyl-group on cytosine carbon-5' position into promoter genes and “CpG islands”.9 
Generally, DNA methylation can reduce the accessibility of transcription machinery to target 
gene promoters leading to lower levels of gene expression.
7 9
 Otherwise, demethylases 
belonging to 10-11 translocation (TET) family of DNA dioxygenases (TET1/2/3) enzymes 
can remove the methyl group from the methylated cytosines leading to a possible increase in 
gene expression.
7 9
 
Histone and non-histone modifications can occur at s ecific amino acid positions. Among 
them, histone acetylation and methylation are the most studied. The first is regulated by two 
families of proteins with the opposing functions: histone acetyltransferases (HATs) and 
histone deacetylases (HDACs) that add and remove one or more acetyl groups mainly at 
lysine residues of histone tails.
8
 
10
 Generally, HATs and HDACs are associated with gene 
activation and repression, respectively.
8 10
 Histone methylation mainly occurs at the lysine 
residues and is mediated by lysine methyltransferases (HMTs) with differential turnover 
rates.
9
 
11
 Overall, the final effect of varies according to the specific site of methylation and the 
number of added methyl groups.
9
 A plethora of methyltransferases, including SET domain 
containing proteins, and demethylases, including Jumonji C (JmjC) domain containing, were 
identified.
9
 
11
 
Different classes of non-coding RNAs control gene expression at different levels.
10 12
 In 
detail, microRNAs (miRNAs) are small non-coding RNA molecules (21-22 nucleotides) 
which bind to specific target mRNAs by blocking their translation or inducing their 
degradation.
10
 Moreover, long non-coding RNAs (lnc-RNAs) are non-coding transcripts that 
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are >200 nucleotides forming RNA-protein interactions to carry out their functions by 
modulating chromatin-modifying complexes and interacting with transcription factors.
10
 
12
 
4. An epigenetic-centered map of cardiac remodeling in HF patients 
Myocyte death, cardiac hypertrophy, alteration of extracellular matrix homeostasis, fibrosis, 
defective autophagy, metabolic abnormalities, and mitochondrial dysfunction are relevant 
epigenetic-sensitive endophenotypes underlying cardiac remodeling and HF pathogenesis 
(Figure 1).
26 1
 
Consistently, the onset of CV diseases in adult life may be explained by the concept of 
“persistent memory”, for which early environmental insults experienced in prenatal or 
perinatal life are translated in epigenetic changes persisting across several generations.
12-14, 
27,28
 
13-15,
 
30,31
 (Figure 2). This effect, known as "transgenerational epigenetic inheritance", is 
largely supported by preclinical models of CV diseases.
12-14 13-15 
Recently, a direct correlation 
between hypermethylation of the sterol regulatory element binding protein 2 (SREBP2) gene 
in fetal aortas and maternal hypercholesterolemia was observed during early atherogenesis.
28 
31
 Further long-term causal relationship studies are needed to dissect the extent of epigenetic-
sensitive changes and maladaptive responses during pregnancy and translate them in useful 
biomarkers for CV primary and secondary prevention (Figure 2).
29
 
30-32
 
4.1 Epigenetics of maladaptive responses in HF patients 
Epigenetic-sensitive molecular networks are crucial during the early adaptive (compensatory) 
responses to cell damage that become “maladaptive” after establishment of chronic stress in 
the heart. We focus on the main intermediate phenotypes (endophenotypes), such as 
metabolic shift, myocardial injury, fibrosis, and mitochondrial dysfunction, and report the 
same findings in humans (Table 1).  
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4.1.1 Metabolic shift  
A switch in cardiomyocyte energy substrate utilization from fatty acids to glucose is the 
metabolic hallmark of HF remodeling, resulting in inefficient energy production.
30,31
 
33,34
 The 
enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2)-DNA methylatransferase 
(DNMT) complex could coordinate hypermethylation and downstream silencing of the 
kruppel-like factor 15 (KLF15) gene in 5 ischemic cardiomyopathy (ICM) vs 6 non-ischemic 
cardiomyopathy (NICM) patients with reduced EF.
30 33
 As consequence, EZH2-DNMT 
complex may be useful to develop personalized approaches to treat ICM by counteracting the 
fetal-like switch program (anaerobic glycolysis).
30 33 
 Moreover, upregulation of histone H3 
lysine 9 (H3K9) demethylase, named Jmjd1a and 2b, reduced H3K9me3 and H3K9me2 
(repression markers) favoring an open chromatin formation in the promoter regions of atrial 
natriuretic peptide (ANP) and brain natriuretic peptide (BNP) genes leading to reactivation of 
fetal genes in 8 dilated cardiomyopathy (DCM) and 8 ICM patients as compared with 8 
nonfailing donor hearts.
31 34 
The first large-scale DNA methylation profile of peripheral blood 
leukocytes isolated from 27 end-stage ICM patients compared to 20 healthy controls revealed 
732 differentially methylated regions (DMRs) in genes related to metabolism and junction 
cellular components.
32 35 
In detail, hypomethylation of mitochondrial inner membrane protein 
like (MPV17L), a negative regulator of apoptosis, and SLC2A1 solute carrier family 2 
member 1 (SLC2A1), a glucose transporter protein, were correlated to higher expression 
levels whereas hypermethylation of plectin (PLEC), encoding a protein involved in actin 
binding and ankyrin binding, corelated with lower protein levels.
32 35 
 Further studies with 
large sample size are needed to validate these results and establish the cause-effect ratio 
underlying myocardial alterations.  
4.1.2 Myocardial injury  
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A large-scale DNA methylation analysis suggested that a parallel hypermethylation of the 
lymphocyte antigen 75 (LY75) and hypomethylation of the adenosine A2a receptor 
(ADORA2A) genes at promoter level was correlated to downregulation of their transcripts in 
LV samples isolated from 10 DCM vs 10 cardiac transplant patients (controls) undergoing 
cardiac catheterization controls.
33 36 
LY75 and ADORA2A are genes not previously associated 
with DCM and could clarify pathogenesis of HF as well as be represent useful biomarkers of 
cardiomyocyte death.
33 36 
Koczor et al.
34
 
37
 reported a global trend of DNA hypermethylation 
resulting in silencing of gene expression in LV samples isolated from 10 DCM patients with 
respect to 10 nonfailing controls. Importantly, four genes with no previously reported role in 
DCM resulted crucial in alteration of cell cycle progression and tight junctions, such as 
thymidine kinase 1 (TK1), claudin 5 (CLDN5), aurora kinase B (AURKB), and butyrophilin-
like 9 (BTNL9).
34
 
37
 However, these genes warrant further study to show how these changes 
may trigger myocardial injuries. For the first time, by using LV samples some authors 
reported that simultaneous DNA hypermethylation and reduced enrichment of histone 3 
lysine 36 tri-methylation (H3K36me3) was correlated to downregulation of double homeobox 
transcription factor (DUX4) gene, involved in reduced cell viability.
35 38
 However, their 
functional role remains to be elucidated in human end-stage cardiomyopathy and further 
studies are needed to determine whether these epigenetic features may predict disease severity 
or normalize with recovery of LV function. 
4.1.3 Fibrosis 
During LV remodeling, collagen increases and occupies the areas between the myocytes and 
the vessels. As a result, reparative (adaptive) fibrosis may adversely progress in maladaptive 
process by influencing tissue stiffness and diastolic ventricular function.
36 39
 By using tissue 
samples isolated from right atrial appendage of 26 patients undergoing elective cardiac-
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bypass surgery, some authors reported that an increasing degree of hypoxia induced a global 
DNA hypermethylation, via DNMT1 and DNMT3B up-regulation, leading to overexpression 
of collagen 1 and alpha-smooth muscle actin (α-SMA) gene.37 40 Interestingly, by using siRNA 
administration to block DNMT3B expression, a reduced collagen 1 and α-SMA gene 
expression was observed in human primary cardiac fibroblasts suggesting a useful putative 
drug target.
37 40
 A possible direct causal-effect relationship between hypermethylation and 
pro-fibrotic phenotype in vivo requires further investigation. 
4.1.4 Mitochondrial dysfunction  
Higher levels of circulating mitochondrial DNA (mtDNA) can contribute to LV remodeling 
and poor prognosis of HF patients.
38,39
 
41
 A differential methylation of some mtDNA genes 
may trigger cardiomyocyte death by silencing survival pathways (hypermethylation) or 
upregulating the expression of proteases (hypomethylation).
40 41 
For the first time, Baccarelli 
et al.
41 42
 measured the levels of mtDNA methylation derived from platelets in genes 
belonging to ATP-synthesis machinery by using samples isolated from 10 patients at risk of 
HF vs 17 healthy controls; CV patients showed significant hypermethylation in 4 genes, 
including mitochondrially-encoded cytochrome-c oxidase I (MT-CO1), mitochondrially-
encoded cytochrome-c oxidase II (MT-CO2), mitochondrially-encoded cytochrome-c oxidase 
III (MT-CO3), and mitochondrially-encoded tRNA leucine 1 (UUA/G) (MT-TL1).
41 42
 This 
evidence may clarify the relationship between platelet mitochondria, DNA methylation, and 
HF suggesting novel predictive non-invasive biomarkers. 
 
4.2“Epitranscriptome”: the next frontier in HF patients 
The epitranscriptome, known as RNA epigenetic code, refers to a plethora of chemical 
modifications in different small RNAs representing an additional layer of gene expression 
regulation
42 
 as well as novel opportunities to establish CV biomarkers.
43,44 
 RNA methylation, 
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mainly on the adenosine base at the nitrogen-6 position (N6-methyladenosine, m6A), has 
been defined a potential regulatory mechanism underlying the cardiomyocyte adaptive 
responses.
44 45
 DNA polymorphisms in the fat mass and obesity associated (FTO) gene, 
encoding for a specific m6A-demethylase, are associated with high risk for obesity, metabolic 
abnormalities, and CV diseases.
45
 Recently, a concomitant decrease in FTO levels and 
increase of m6A content in RNA was observed in ischemic human hearts.
44 45
 Another form 
of RNA modification is the switch from adenosine to inosine (A-to-I), known as RNA editing, 
which is mediated by the adenosine deaminase acting on RNA (ADAM) enzymes, as strong 
contributors to atherosclerosis.
45 46
 Clinical evidence reported an increased A-to-I editing of 
the mediator complex subunit 13 (MED13) mRNA in blood samples isolated from cyanotic 
congenital heart pediatric patients (n=19) compared to controls (n=13)
47
, suggesting a putative 
pathogenic
46 
 and prognostic role.
47 48
 However, there are not studies investigating the role of 
epitranscriptome in HF patients. 
4.3 Epigenetics in patients with advanced HF on waiting list for HTx  
HTx is the only available long-term treatment for terminal HF patients.
48
 
49
 Despite current 
immunosuppressive regimens, the allograft rejection rate is high and clinically asymptomatic 
making the diagnosis very difficult.
49 50
 Predictive epigenetic indicators may identify patients 
at high risk for post-transplant complications.
 
Duong et al.
50 51
 reported that pro-inflammatory 
miR-10a, miR-155, miR-31, and miR-92a were differentially expressed both in serum and 
tissue samples isolated from 30 patients with acute allograft rejection respect with 30 healthy 
controls, suggesting a putative role as useful non-invasive biomarkers. Interestingly, some 
authors suggested that circulating cell-free (cfDNA) donor-derived DNA might also provide a 
non-invasive diagnosis of acute rejection.
51 52
 Thus, further clinical studies should focus on 
DNA methylation levels in cfdDNA molecules, which may represent an early and non-
invasive predictive biomarker of HTx complications. 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
13 
 
5. Rethinking the transgenerational effect in the stratification of the natural history of 
HF 
Development HF syndrome reflects a long lag time between onset and real clinical 
manifestations providing a huge opportunity for implementation of inexpensive lifestyle 
interventions to reduce mortality and morbidity rate.
3,4
 Much attention should be given to 
stage A patients which did not yet develop structural heart changes but are likely in 
progression of HF.
3
 Since numerous epigenomic patterns exist in human 
adaptive/maladaptive responses (Table 1), it is need to also confirm or not if these molecular 
signatures can track disease progression. These responses are crucial to establish epigenomic 
assays for assessing prognosis in HF.  
Early stages of CV lesions are already set during human fetal development providing 
epigenetic tracks of vascular damage
12,13,28 13,14,30,31
; thus, an optimal experimental strategy 
should address the putative role of “epigenetic memory” in the insurgence of HF (Figure 2). 
We revisited this concept by proposing the EPi-transgeneratIonal networK mOdeling-
STratificatiOn of heaRt Morbidity (EPIKO-STORM) platform, as clinical integrated research 
program based on “epigenetics memory” and network-based analyses to stratify the natural 
history of HF. The idea of this proposed platform is to monitor large prospective mother-child 
cohorts to clarify how, when and where maternal risk factors, e.g. diabetes, dyslipidemias, 
CHD with no myocardial infarction (stage A) can epigenetically impact early fetal 
development making a subject more susceptible to HF later in life.  
There are many concerns on the potential windows of vulnerability in which detrimental 
exposure can epigenetically impact crucial nodes (genes or proteins) underlying the 
development of HF from high risk patients (stage A). We remark three times for which 
epigenetic-sensitive sensors might play a role in pathogenesis and progression of HF (window 
1: “early”, <6 months to 15 years; window 2: “later”, 15-50 years; window 3: >50 years) 
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(Figure 2). The epigenetic plasticity to environmental risk factors is highly relevant from 
embryonic development to early post-natal life (window 1). This impacts on individual 
genetic make-up by modulating putative maladaptive responses when a subject experience the 
same in utero insults (or other) in post-natal life. Moreover, the inherited epigenetic tracks 
may be further impacted by acquired structural and functional cardiac alterations in adulthood 
leading to synergic effects in progression of HF (window 2) until conclamate disease 
(window 3). Much difficult is to determine if epigenetic-sensitive nodes can be further 
impacted by environmental factors in end-stage failing hearts (window 3). Evidence reported 
that epigenetic sensors may be useful biomarkers. Whether these sensors can be useful to 
improve the quality of care and quality of life of HF patients that experience high rate of 
hospitalization remains undetermined.  
A strength of EPIKO-STORM platform would be to combine liquid biopsy approaches and 
network analysis which can identify non-invasive biomarkers arising from cardiomyocytes 
death or other common circulating cells (e.g., fibroblasts) at different time points.
52
 
53
 Indeed, 
the widely diffuse tissue biopsy from explanted hearts may be altered during handling 
(degradation, missing oxygenation, innervation and worsening LV function) and difficult to 
obtain.
53 54
 Since epigenetic-sensitive changes largely vary over time, the possibility of 
studying these patterns at different time-points during life may be an add value respect with 
the most frequent cross-sectional analysis (one time-point measure).
54 55
 This strategy is 
particularly useful to design longitudinal analysis by following the “transgenerational effect” 
of maladaptive responses in high risk families. In this way, the EPIKO-STORM platform may 
identify novel circulating epigenetic signatures mirroring the “cardiac” interactome and 
monitor their variations from the fetal-perinatal stage until childhood and older age. This 
comprehensive staging approach may provide earlier identification and management of at-risk 
subjects before the development of HF (Figure 2). For this reason, future studies would 
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greatly benefit from using the EPIKO-STORM platform to provide novel biomarkers for 
disease staging mainly at two time points: 1) identification of asymptomatic subjects with 
increased genetic risk or structural/functional dysfunction (primary prevention) and 2) 
monitoring of patients with severe or end-stage HF (secondary prevention). Overall, this 
strategy could open an important new avenue of research because the epigenome may 
represent a drug discovery target for novel HF therapy. 
6. Advanced omics technologies and bioinformatic tools to identify novel useful 
epigenetic biomarkers in HF  
6.1 Omics platforms and longitudinal analysis of epigenetic tracks in HF patients 
Since next generation sequencing (NGS) tools become more rapid and less expensive, 
researchers are turning toward unbiased large-scal  analyses on multiple omics data to better 
understand, identify, and treat HF patients (Table 2).
55-58 56-59
 Genomics enlarged the range of 
HF susceptibility genes and improved the performance of screening tests but offered a 
knowledge at a limited resolution level.
55 56 
Transcriptomics, proteomics and metabolomics 
may provide insight into disease origin and may be possible clinical applications useful to 
provide a more accurate prediction of the long-term clinical course of a patient.
56-59 57-59
 On 
the other hand, only epigenome-wide association studies (EWAS) integrated with current 
clinical approaches may better clarify the mechanistic role of molecular sensors modulating 
the gene-environment interplay in CV patients (Figure 3).
60-63
 In table 1, we reported some 
platforms which may powerfully aid to: 1) discriminate patients with common clinical 
phenotypes (deep-phenotyping), 2) identify more penetrant causal-effect endophenotypes, and 
3) customize drug therapies.
60 
 Despite increasing advance, the use of epigenomics 
approaches also presents several limitations mainly owing to the confounding effects related 
to the heterogeneity of the whole cardiac tissue.
64,65 
Indeed, experimental approaches should 
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major investigate circulating cells and their products in blood samples (liquid biopsy 
strategy), including endothelial progenitor cells (EPCs), cfDNA, and circulating histones. In 
this way, we can provide specific and non-invasive biomarkers for diagnosis and prognosis of 
many CV diseases.
52 53
 For this aim, prospective population studies will strongly help us to 
find novel targets for risk evaluation, diagnosis and treatment strategies.
62-64 
 
6.2 Advanced bioinformatic tools to identify protein-protein interactions (PPIs) 
Network analyses are useful to advance our CV clinical practice.
65-68 66-70
 Respect with the 
current reductionist approach, network analyses focus on human diseases as consequence of 
alterations in gene-gene interactions rather than a single defect in a single gene.
65-68 66-70
 This 
approach may aid to clarify the complex effects of multiple exposures on molecular networks 
perturbing the cardiac interactome at individual level.
65-68 66-70
 Network-oriented analyses may 
capture crucial nodes (genes, proteins or other) or disease modules (subgroups of gene 
products with the same or similar functions) by using specific criteria measuring network 
topology.
65-68 66-70 
A large panel of quantitative platforms is available including protein-
protein interactions (PPIs) networks, in which pathogenic proteins are the nodes linked by 
physical and functional interactions (e.g., GenePanda, DIAMOnD) regulatory networks, 
thereby interactions between a transcription factor and its target gene are investigated (e.g., 
PANDA) as well as co-expression networks, in which genes with concordant expression 
profiles are correlated (e.g., SWIM and WGCNA).
65-68 66-70
 Some of these applications, 
mainly PPI networks, were applied to identify crucial nodes underlying the heart remodeling 
in patients.
69-72 71-74
 Of note, by using machine learning algorithms to predict PPIs or 
predictive models from clinical data stored in big consortia, we may provide an in-depth 
understanding of disease as well as gain the goals of precision medicine and personalized 
therapy of HF.
73,74 75,76
 However, enthusiasm around artificial intelligence analysis should be 
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tempered as the road from bench to bed is complex and time-consuming owing to their "black 
box" nature, also (Figure 4). This intrinsic criticism means that we will never aware about the 
logic criteria used by the algorithms to make the final decision, thus physicians can only make 
final decisions according to current guidelines, own experience and intuition. To potentially 
accelerate this direction, it is needed to apply rigorous scientific methodology testing the 
artificial intelligence tools in clinical practice.  
7. The current and future contribution from epigenetics to precision medicine of HF  
To date, a low number of basic findings has been effectively translated in HF clinical practice, 
such as BNP, N-terminal pro-B-type natriuretic peptide (NT-proBNP), creatine 
phosphokinase (CPK), and high-sensitive cardiac troponin (hscTn), which are well 
established indicators of myocardial injury/fibrosis and its progression.
3
 Nevertheless, an 
untimely detection and inter-individual differences in the baseline features still exist
75 77
, thus, 
the current clinical practice would benefit from more accurate non-invasive biomarkers that 
might be a realty in the future clinical practice of HF. In this context, interest is growing about 
nerve growth factor (NGF), that is expressed by ischemic myocytes, as well as circulating 
progenitor cell (CPC) dysfunction in diabetes which seems to be a key factor in 
microcirculation disruption.
76,77 78,79
 
7.1 Stratification of the natural history of disease in different HF phenotypes 
Nowadays, evidence regarding epigenetic-sensitive causal pathways are lacking in HFrEF, 
HFmrEF, and HFpEF. We reported some examples of epigenetic signatures in different HF 
phenotypes. Recent evidence reported that levels of circular RNA, named circRNA MICRA, 
were lower in the subgroup of post-MI patients associated with reduced EF after 4 months 
from measurements with respect to HFmrEF or HFpEF groups.
78 80 
This suggests MICRA as 
potential predictive biomarker for HFrEF phenotype after MI.
78 80 
CRT is associated with 
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improved performance and survival in patients with advanced HF. A clinical trial reported 
that HFrEF patients, classified as “responders” to CRT showed an overexpression of 19 
circulating miRNAs associated with improvement of systolic function.
79 81
 In contrast, non-
responders patients showed a downregulation of 6 different circulating miRNAs. This 
suggests that a specific miRNA profile may be useful as predictor of response to CRT in 
HFrEF.
79 81 
By using peripheral blood and cardiac cells, some authors performed the first 
epigenome-wide association study in HFmrEF patients.
80 82 
As a result, DNA 
hypomethylation of the natriuretic peptide A and B (NPPA and NPPB) genes at promoter 
level was reported in 41 HFmrEF patients vs 31 controls leading to upregulation of ANP and 
BNP proteic products, respectively.
80 82 
The key message of this study is that detection of 
DNA hypomethylation in NPPA/NPPB genes in peripheral blood may mirror the cardiac 
epigenome and represent a potential diagnostic biomarker of HFmrEF patients.
80 82
 The high 
phenotypic heterogeneity of HFpEF is a major challenge to identification of this patients and 
the development of new therapies.
81 83
 Recent evidence suggested that miRNAs might 
discriminate between HFrEF and HFpEF phenotypes, as well as provide a better insight in 
their differential pathophysiology of disease.
82,83 84,85 
In detail, differential expression of miR-
30c, miR-146a, miR-221, miR-328, and miR-375, miR-125a-5p, miR-190a, miR-550a-5p, 
and miR-638 may improve the predictive value of BNP as well as the differentiation of 
HFpEF from HFrEF supporting additional diagnostic strategies.
82,83 84,85
 We noted that the 
most of clinical findings about discerning HF phenotypes are related to miRNAs, likely 
because they are stable circulating molecules and their detection is non-invasive, thus 
representing ideal biomarkers of disease and therapeutic strategies.
84 86
 
7.2 Personalized therapy 
Could the reversal of aberrant epigenetic networks be an add value to the current evidence-
based guidelines in HF management? Moreover, which subgroups of patients may have some 
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benefits from an epidrug rather than another? And in which doses? Monotherapy or 
polytherapy? These are crucial questions that are still waiting a response from the research 
community. Several evidence reported that some classes of epidrugs may act as 
immunosuppressive agents by modulating the activity of T-reg cells in post-transplant 
patients.
6
 However, there are not clinical trials investigating the role of epidrugs in preventing 
organ reject after Htx. In Table 3, we reported the currently available trials which 
investigated the effect of monotherapy/polytherapy epidrugs in HF management. Preclinical 
evidence suggests that “pleiotropic” effects of statins, as HMG-CoA reductase inhibitors, may 
improve survival in ischemic and non-ischemic HF by regulating the autonomic nervous 
system through angiotensin II and nitric oxide modulation.
85 87
 Statins act as epidrugs by 
inhibiting the HDAC activity thus shifting the histone balance toward an acetylated state, 
marker of active transcriptional activity.
86 88 
However, preliminary human studies reported 
mixed results. Indeed, Horwich al.
85 89
 reported that short-term statin treatment did not result 
in a significant decrease in autonomic nervous system activation in HF patients.
87
 In contrast, 
a large metanalysis of 13 randomized trials reported that administration of lipophilic statins 
(e.g., atorvastatin) significantly decreased all-cause mortality, hospitalization for worsening 
HF, and low-density lipoprotein cholesterol, independently from age, baseline LVEF, and 
cause of HF.
88 90
 Thus, there is no evidence to recommend their routine use in HF therapy. 
Interestingly, a dietary supplementation with fish-oil-derived long-chain omega-3 
polyunsaturated fatty acids (PUFA) may have hypotriglyceridemic, anti-inflammatory, anti-
arrhythmic, and anti-thrombotic effects by altering the global DNA methylation profile in 
blood leukocytes.
89 91
 The large-scale, randomized, double-blind study (the GISSI Heart 
Failure project) demonstrated that 1 g per day of omega 3 is associated with a small reduction 
(9%) in mortality and admissions to hospital for CV events in HF patients.
90 92
 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
20 
 
Regarding polytherapy, a completed randomized trial demonstrated that isosorbide dinitrate 
(ISDN) combined with a global inhibitor of DNA methylation, as hydralazine, did not exert 
beneficial effects in HFpEF with respect to controls
91 93
, whereas this polytherapy is already 
part of the HFrEF (stage C) standard of the care.
3
 As mentioned, numerous studies based on 
epigenetic therapy have no positive results and one reason may be that all these agents are not 
specific enough but universal, therefore the drugs cannot selectively target the pathogenic 
epigenetic changes in HF patients. In this way, engineered CRISPR/Cas9 systems and, others 
innovative systems, are being tested in vivo to direct specific epigenetic players to target 
genes providing novel strategies to establish epigenetic therapy in humans.
92 94
 Also, we 
included a number of clinical trials, generated from the website https://clinicaltrials.gov/, that 
are ongoing or completed in the last ten years but currently without any results 
(Supplementary Table 1, Supplementary Table 2). 
8. New perspectives  
Despite clinical epigenetics is still in its infancy, it promises to become a new avenue to 
dissect HF phenotypes at molecular level. Nowadays, tissue heterogeneity has not been fully 
explored with specific focus in the setting of HF. Remarkably, it is needed to assess if 
methylation changes in circulating leukocytes may reflect myocardial processes providing 
reliable biomarkers. Also, to ensure rigor and reproducibility when designing association 
studies, avoiding contamination, both rigorous sample and sampling considerations, 
accounting for analytical variability, and a better understanding of biological variability and 
tissue specificity of these epigenetic signatures, are desiderable. Artificial intelligence might 
offer novel opportunities to bridge these gaps but, today, we are still far from clinical 
application. Current clinical research in HF points to the hypothesis that complex molecular 
networks are regulated by genetic-epigenetic interplay and activated in the failing 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
21 
 
myocardium in response to the original triggering cause, leading to re-expression of fetal 
genes, upregulation of fibrosis-related genes, and others maladaptive responses. The 
epigenome regulates the expression of early maladaptive responses, and recent evidence 
suggests that part of the chromatin remodeling may be altered by diet and other environmental 
risk factors. Several epigenetic-sensitive changes may enlarge opportunities to explain the 
missing hereditability in HF (Table 1). Moreover, gene polymorphism investigation may also 
improve our understanding of epigenetics. For example, the insertion/deletion of intron 16 in 
the ACE gene acts as marker for a functional polymorphism that provides gene-environment 
interactions leading to possible explanations for mixed findings in clinical setting.
93 95
 
Most of clinical evidence arose from DNA methylation profile performed in LV tissue 
samples and circulating miRNAs. Obviously, investigations in human tissues are restricted 
because genome sequencing needs a relatively large amount of biospecimens, which are not 
easily available from living patients. Despite increasing advance, the clinical use of 
epigenomics approaches also presents several limitations mainly owing to the confounding 
effects related to the heterogeneity of the whole cardiac tissue. Indeed, experimental 
approaches should major investigate if tissue-related epigenetic signatures may be reflected in 
circulating cells and their products in blood samples to provide non-invasive biomarkers 
(liquid biopsy strategy).
65,80 53
 Thus, we are still not able to identify epigenetic signatures 
discriminating the different HF phenotypes (HFrEF, HFpEF, HFmrEF).  
Since the reversible nature respect with genetic mutations, epigenetic-sensitive changes are 
useful drug targets tested in several clinical trials. The BETonMACE ongoing phase III trial 
(NCT02586155) is assessing the ability of apabetalone in reducing both inflammation and 
adhesion molecule gene expression in post-ACS diabetic patients with low high-density 
lipoprotein C (Table 3). Importantly, apabetalone is highly selective for the second 
bromodomain (BD2) within the bromodomain and extraterminal proteins (BETs), which bind 
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to acetylated histones and transcription factors providing specific biological effects with 
potentially major benefits for high-risk CV patient by maintaining a safety profile.
94 96 
Major 
efforts should be done to identify in which type of cells apabetalone can exert its beneficial 
effect to avoid side-effects; however, it would be interesting to investigate if this epidrug 
might be also effective in prevention or management of HFpEF that results associated with 
inflammation, hypertension and metabolic dysfunction (T2D type 2 diabetes and obesity).
3
 
Indeed, it should be noted that the epigenome is highly spatio-temporal specific and each 
epigenetic change can regulate a cassette of downstream genes; therefore, the use of epidrugs 
is not totally specific leading to a range of putative side-effects representing one of the main 
current challenge in clinical trials. In this highly complex and dynamic environment, current 
investigation methodology based on matching of clinical, biochemical and instrumental 
variables, to draw study population profile is no more fit for perspective research. Now, all 
omics platforms are restricted to a bench approach in CV field. If adoption of big data 
analysis with deep computing or artificial intelligence will supply this gap remains a 
challenge question. In this way, we propose the EPIKO-STORM, a longitudinal clinical 
platform combining transgenerational effect and network-oriented analyses to gain 
personalized “precision medicine” therapy of HF patients.  
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Legends to figures: 
Figure 1. Epigenetics, maladaptive responses and heart failure. A plethora of epigenetic-
sensitive mechanisms could be crucial pathogenic determinants leading to many diseases 
associated with heart failure. When environmental insults persisting over time, a chromatin 
remodeling may trigger a switch from adaptive vs maladaptive responses, including metabolic 
shift, myocardial damage, fibrosis, and mitochondrial dysfunction. These molecular 
perturbations could be related to different cardiac phenotypes, including HFrEF, HFmrEF, 
and HFpEF. 
Abbreviations: CHD: Coronary Heart Diseases; DCM: Dilated Cardiomyopathy; HFrEF: Heart Failure Reduced Ejection 
Fraction; HFpEF: Heart Failure Preserved Ejection Fraction; HFmrEF: Heart Failure Mid-Range Ejection Fraction; ICM: 
Ischemic Cardiomyopathy. 
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Figure 2: Epigenetics of maladaptive responses in HF patients and EPIKO-STORM.  
At the top of picture, we design an epigenetic-centered map about molecular networks 
underlying maladaptive responses in HF patients (see the text for more details). Moreover, we 
emphasize the importance of studying these epigenetic sensors early during the fetal 
development and progressively later in life to trace longitudinal dynamic trajectories useful to 
HF precision medicine and personalized therapy. In particular, we propose a program of 
clinical research, named EPIKO-STORM, focusing on the potential impact of 
transgenerational effect in identifying novel non-invasive epigenetic biomarkers able to 
monitor each molecular variation from the fetal-perinatal stage to childhood, older age, and 
subsequent generations. It poses major attention to detect maternal risk factors and early 
epigenetic-sensitive signatures of cardiac remodeling in stage A patients.  
Abbreviations: CHD: coronary heart disease; EPIKO-STORM: EPi-transgeneratIonal network mOdeling-STratificatiOn of 
heaRt Morbidity; HF: heart failure, MI: myocardial infarction. 
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Figure 3: Full-spectrum of epigenomic tools in clinical research programs. The advance 
of NGS techniques has enlarged the opportunities for measurement of epigenetic-sensitive 
changes in human samples, such as DNA methylation, histone modifications, and 
microRNAs. These molecular signatures can be detected in PBMNCs, whole blood, saliva, 
plasma/serum, and different tissues. By using these applications, we can provide a huge 
amount of big data that have to be analyzed through potent bioinformatic algorithms, such as 
network-oriented analyses. The ultimate goal is to identify the individual interactome in heart 
failure patients to improve personalized therapy of disease. 
Abbreviations: DNMT: DNA Methyltransferase; HPLC: High Performance Liquid Chromatography; MiRNAs: MicroRNAs 
NGS: Next Generation Sequencing; PBMNCs: Peripheral Blood Mononuclear Cells. 
 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
27 
 
Figure 4: Clinical practice of HF: a role for artificial intelligence? Despite limitations, 
current reductionist approach based on clinical evaluation, imaging, surgery and physician-
patient fidelity remains irreplaceable for effective outcomes in HF management. Artificial 
intelligence applications might support physicians in decision-making but, nowadays, are 
challenged by intrinsic criticisms. Despite artificial intelligence is a “black box”, we need to 
merge these platforms in large clinical trials in order to test their possible use in clinical 
practice. 
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Table 1. Some examples of epigenetic signatures leading maladaptive responses in HF 
patients. 
Epigenetic 
mechanism 
Region Sample size Sample source Platform Molecular effect 
Signaling 
pathway 
Phenotypic effect 
    
Tissue 
biopsy 
   
DNA 
hypermethylation 
of KLF15  
 
[33] 
Promoter  
5 ICM with 
reduced EF vs 
6 NICM 
patients  
(M; 49-70 
years) 
LV biopsy 
llumina 
Infinium Human 
Methylation450 
Beadchip 
Silencing of gene 
expression 
Cardiac switch 
from an 
oxidative 
metabolism vs 
anaerobic 
glycolysis 
Fetal-like  
phenotype 
Demethylation of 
H3K9 at ANP and 
BNP 
 
[34] 
Promoter  
8 ICM and 8 
DCM patients 
with reduced 
EF and vs 8 
non failing 
controls 
(M and F; 45-
60 years) 
LV biopsy ChIP assays 
Activation of gene 
expression 
Cardiac switch 
from an 
oxidative 
metabolism vs 
anaerobic 
glycolysis 
Fetal-like  
phenotype 
DNA 
hypermethylation 
of LY75 
Promoter  
10 non-
ischemic, 
idiopathic 
DCM patients 
with reduced 
EF vs 
10 healthy 
subjects 
(M and F; 53-
61 years) 
LV biopsy 
 
Infinium Human 
Methylation 27 
platform 
Silencing of gene 
expression 
Collagen-
binding 
receptor and G 
protein-
coupled 
receptor 
Myocardial  
damage 
DNA 
hypomethylation 
of ADORA2A 
 
[36] 
DNA 
hypermethylation 
of TK1, 
CLDN5, 
AURKB, 
BTNL9 
 
[34] 
Promoter  
10 DCM 
patients with 
reduced EF vs 
10 healthy 
subjects 
(M and F; 50-
60 years) 
LV biopsy MeDIP 
Silencing of gene 
expression 
Cell cycle 
progression 
and tight 
junctions 
Myocardial  
damage 
DNA 
hypermethylation 
and reduced 
enrichment of 
H3K3me3 at 
DUX4 
Promoter 
 
4 patients 
undergoing 
HTx vs 4 
healthy 
controls 
(M and F; 41-
LV biopsy 
MeDIP;  
ChIP 
 
Downregulation 
of gene expression 
Reduced cell 
viability. 
Myocardial  
damage 
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[38] 
64 years) 
DNA 
hypermethylation 
of α-SMA and 
collagen 1 
 
[40] 
Not 
defined 
26 patients 
undergoing 
cardiac-
bypass 
surgery (case-
only, M and 
F; 60-80 
years) 
RA biopsy 
Quantitative 
real-time PCR; 
Western 
blotting; 
RNA 
interference 
Activation of gene 
expression 
Increased 
collagen 
deposition 
Fibrosis 
    
Liquid-based 
assays 
   
Hypermethylation 
of mtDNA at 
MT-CO1, MT-
CO2, MT-CO3 
and MT-TL1 
 
[42] 
Not 
defined 
Platelet-
derived 
mtDNA from 
patients at 
high-risk of 
HF 
(M and F; 22-
83 years) 
Peripheral 
blood 
Bisulfite-PCR 
pyrosequencing 
Not defined 
Cardiac cell 
death 
Myocardial  
damage 
 
DNA 
hypomethylation 
of MPV17L, 
SLC2A1 
Promoter  
27 ICM 
patients with 
reduced EF 
vs 20 healthy 
controls 
(M and F; 39-
95 years) 
 
PBMNCs 
 
RRBS 
Higher levels of 
transcription 
 
 
Lower levels of  
Apoptosis, 
glucose 
uptake, and 
cytoskeleton 
Metabolic  
unbalance 
DNA 
hypermethylation 
of PLEC 
 
[35] 
transcription 
    
Combination of 
tissue and 
liquid-based 
assays 
   
DNA 
hypermethylation 
of LY75 
 
[80] 
Promoter 
18 DCM 
patients and 8 
healthy 
controls 
LV biopsy  
and 
peripheral blood 
Infinium human 
methylation 450 
 
Lower levels of 
transcription 
 
Cardiac 
development 
and muscle 
function 
Myocardial  
damage 
Abbreviations: α–SMA: Collagen 1 And Alpha-Smooth Muscle Actin; ADORA2A: Hypomethylation Of The Adenosine A2a Receptor; 
ANP: Atrial Natriuretic Peptide; AURKB: Aurora Kinase B; BNP: Brain Natriuretic Peptide; BTNL9: Butyrophilin-Like 9; CLDN5: 
Claudin 5; DCM: Dilated Cardiomyopathy; DUX4: Double Homeobox Transcription Factor; EF: Ejection Fraction; HF: Heart Failure; 
H3K9: Histone 3lysine 9; H3K3: Histone 3 Lysine 9; Htx: Heart Transplantation; ICM: Ischemic Cardiomyopathy; KLF15: Kruppel Like 
Factor 15; LV: Left Ventricle; LY75: Lymphocyte Antigen 75; MeDIP: Methylated DNA Immunoprecipitation; MPV17 Mitochondrial Inner 
Membrane Protein Like; Mtdna: Mitochondrial DNA; MT-CO1: Mitochondrially Encoded Cytochrome C Oxidase I; MT-CO2: 
Mitochondrially Encoded Cytochrome C Oxidase II; MT-CO3: Mitochondrially Encoded Cytochrome C Oxidase III; MT-TL1: 
Mitochondrially Encoded Trna Leucine 1 (UUA/G); NICM: Non-Ischemic Cardiomyopathy; PBMNCs:Peripheral Blood Leukocytes; PLEC: 
Plectin; RA: Right Atrial; SLC2A: Glucose Transporter Protein; RRBS: reduced representation bisulfite sequencing; SLC2A1:Solute Carrier 
Family 2 Member 1; TK1: Thymidine Kinase 1. 
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Table 2. Selected Examples of omics studies in HF patients. 
OMICS 
STUDY 
TYPE 
SAMPLE 
SIZE 
SAMPLE 
SOURCE 
PLATFORM FINDINGS 
Genomics 
 
[56] 
Meta-
analysis of 4 
prospective 
cohorts 
from 
CHARGE 
Consortium 
23,821 
cohort 
participants 
Peripheral blood 
Affymetrix 
6.0; 
Illumina 
370CNV; 
Affymetrix 
500K and 
50K; 
Illumina 550K 
v3  
2 SNPs were associated with incident HF (1 
in European-ancestry and 1 in African-
ancestry participants) 
Transcriptomics 
 
[57] 
Case-only 
43 HF 
patients  
Endomyocardial 
biopsy samples 
Human 
Genome U133 
Plus 2.0 Array 
from 
Affymetrix 
Transcriptome from tissue biopsy contains 
sufficient information to discriminate poor 
from good prognosis 
Proteomics 
 
[58] 
 
HOMAGE 
study 
Discovery 
set with 286 
cases (HF) 
and 591 
controls; 
Replication 
set with 276 
cases (HF) 
and 280 
controls 
Plasma 
Olink Proseek 
Multiplex 
CVD II, III 
Increased biomarkers of inflammation, 
apoptosis, matrix remodeling and impaired 
blood pressure control 
and metabolism 
Metabolomics 
 
[59] 
CATHGEN 
study 
HFpEF 
cases 
(N=282); 
HFrEF 
controls 
(N=279); 
controls 
(N=191) 
Plasma LC-MS/MS 
Increased long chain acylcarnitines in states 
of inefficient β‐oxidation differentially 
elevated in HFpEF and HFrEF 
Abbreviations: CATHGEN: CATHeterization GENetics; CHARGE: Heart And Aging Research In Genomic Epidemiology; HFpEF: Heart 
Failure Preserved Ejection Fraction; HFrEF: Heart Failure Reduced Ejection Fraction; HOMAGE: Heart 'omics' in AGEing; LC-MS/MS: 
Liquid Chromatography With Mass Spectrometry; SNPs: Single Nucleotide Polymorphisms. 
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Table 3. Epigenetic therapy in HF clinical trials. 
Abbreviations: BETs: Bromodomain And Extraterminal proteins; CHD: Coronary Artery Disease; CHF: Congestive Heart Failure; ISDN: 
Isosorbide Dinitrate; N/A: Not Available; NCT: Number Of Clinical Trial, PUFA: Polyunsaturated Fatty Acids; T2D: Type 2 Diabetes. 
Type of study Epidrug Participants 
HF 
phenotype 
Objectives 
Phase/ 
Status 
Ref. 
   
Monotherap
y 
   
Controlled, 
randomized 
(NCT0023348
0) 
Atorvastati
n 
27 HF 
 to investigate 
potential 
beneficial effects 
of statins in 
reducing 
sympathetic 
nervous system 
activation, 
myocardial 
remodeling, and 
immune 
activation in HF. 
Phase 4/ 
Complete
d 
[89] 
Controlled, 
randomized 
(NCT0033633
6) 
PUFA 
or 
Rosuvastati
n 
6975 HF 
 To demonstrate 
that long term 
administration of 
PUFA or 
rosuvastatin is 
more effective 
than the 
corresponding 
placebo in HF 
patients, treated 
at the best of 
recommended 
therapies. 
Phase 3/ 
Complete
d 
[92] 
Metanalysis of 
13 randomized 
trials  
Atorvastati
n (10 
trials), 
simvastatin 
(2 trials), 
and 
pitavastatin 
(1 trials) 
1,532  HF 
 to systematically 
review all 
randomised 
controlled trials 
evaluating the 
effects of 
lipophilic statins 
in HF patients. 
N/A [90] 
   Polytherapy    
Controlled, 
Randomized 
(NCT0151634
6) 
Hydralazine 
(DNA 
methylation 
inhibitor)  
And/or 
ISDN 
 
54 
HF, 
CHF 
 To test the effect 
of prolonged 
therapy (24 
weeks) with 
isosorbide 
dinitrate ± 
hydralazine on 
arterial wave 
reflections.  
Phase 2/ 
Complete
d 
[93] 
 
Controlled, 
randomized 
(NCT0258615
5) 
Apabetalon
e 
2425 T2D 
 to determine 
whether inhibition 
of BETs in high-
risk T2D patients 
with CHD 
increases the time 
to major adverse 
cardiovascular 
events 
Phase 3 [96] 
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 The goal of this review is to highlight as failing hearts undergo epigenetic-sensitive 
maladaptive responses. 
 Network-oriented analysis and artificial intelligence can advance clinical practice in 
HF management. 
 The EPIKO-STORM is a platform which might improve precision medicine of HF. 
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